(Q46042915)

English

Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study

scientific article published in June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jeffrey A Meyerhardt

7

object named as

Jeffrey Meyerhardt

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

author name string

Nadine A Jackson

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

José Barrueco

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

Raoudha Soufi-Mahjoubi

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

John Marshall

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

Edith Mitchell

5

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

Xiaoxi Zhang

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

language of work or name

0 references

publication date

1 June 2009

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

115

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

12

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

2617-2629

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Elderly patients with advanced colorectal cancer: which therapy is the safest?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer screening in elderly patients: a framework for individualized decision making

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic overview of chemotherapy effects in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of cancer in the older person: a practical approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Managing older patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Provider roles in the recruitment of underrepresented populations to cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Participation of patients 65 years of age or older in cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24305

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24305

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19382200

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46042915&oldid=2093852418"